Anti-Telomerase reverse transcriptase antibody [Y182] (ab32020)
- Product nameAnti-Telomerase reverse transcriptase antibody [Y182]See all Telomerase reverse transcriptase primary antibodies ...
- DescriptionRabbit monoclonal [Y182] to Telomerase reverse transcriptase
- Tested applicationsWB, ICC/IF, Flow Cyt, IP, IHC-P, IHC-Fr more details
- Species reactivityReacts with: Cow, Human
Does not react withMouse, Rat
Synthetic peptide corresponding to residues in the C terminus of human Telomerase reverse transcriptase.
- Positive controlWB: Hela cell lysate. IHC-P: Human lung adenocarcinoma.
- General notesProduced under U.S. Patent No. 5,675,063.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
- Concentration information loading...
- Purification notesCells supernatant
- Clonality Monoclonal
- Clone numberY182
- Research Areas
Our Abpromise guarantee covers the use of ab32020 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/1000. Detects a band of approximately 122 kDa (predicted molecular weight: 127 kDa).|
|ICC/IF||ICC/IF: 1/50 - 1/100.|
|Flow Cyt||Flow Cyt: 1/100.|
|IP||IP: Use at an assay dependent dilution.|
|IHC-P||IHC-P: Use at an assay dependent dilution. PubMed: 20367640|
|IHC-Fr||IHC-Fr: Use a concentration of 0.75 µg/ml. PubMed: 17982423|
- FunctionTelomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis.
- Tissue specificityExpressed at a high level in thymocyte subpopulations, at an intermediate level in tonsil T lymphocytes, and at a low to undetectable level in peripheral blood T lymphocytes.
- Involvement in diseaseNote=Activation of telomerase has been implicated in cell immortalization and cancer cell pathogenesis.
Defects in TERT are associated with susceptibilty to aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.
Note=Genetic variations in TERT are associated with coronary artery disease (CAD).
Defects in TERT are a cause of dyskeratosis congenita autosomal dominant (ADDKC) [MIM:127550]; also known as dyskeratosis congenita Scoggins type. ADDKC is a rare, progressive bone marrow failure syndrome characterized by the triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy.
Defects in TERT are a cause of susceptibility to pulmonary fibrosis idiopathic (IPF) [MIM:178500]. Pulmonary fibrosis is a lung disease characterized by shortness of breath, radiographically evident diffuse pulmonary infiltrates, and varying degrees of inflammation and fibrosis on biopsy. It results in acute lung injury with subsequent scarring and endstage lung disease.
- Sequence similaritiesBelongs to the reverse transcriptase family. Telomerase subfamily.
Contains 1 reverse transcriptase domain.
- DomainThe primer grip sequence in the RT domain is required for telomerase activity and for stable association with short telomeric primers.
The RNA-interacting domain 1 (RD1)/N-terminal extension (NTE) is required for interaction with the pseudoknot-template domain of each of TERC dimers. It contains anchor sites that bind primer nucleotides upstream of the RNA-DNA hybrid and is thus an essential determinant of repeat addition processivity.
The RNA-interacting domain 2 (RD2) is essential for both interaction with the CR4-CR5 domain of TERC and for DNA sythesis.
modificationsUbiquitinated, leading to proteasomal degradation.
Phosphorylation at Tyr-707 under oxidative stress leads to translocation of TERT to the cytoplasm and reduces its antiapoptotic activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention. Phosphorylation by the AKT pathway promotes nuclear location.
- Cellular localizationNucleus > nucleolus. Nucleus > nucleoplasm. Nucleus. Chromosome > telomere. Cytoplasm. Nucleus > PML body. Shuttling between nuclear and cytoplasm depends on cell cycle, phosphorylation states, transformation and DNA damage. Diffuse localization in the nucleoplasm. Enriched in nucleoli of certain cell types. Translocated to the cytoplasm via nuclear pores in a CRM1/RAN-dependent manner involving oxidative stress-mediated phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2 retains TERT in the nucleus. Translocated to the nucleus by phosphorylation by AKT.
- EST2 antibodyhEST2 antibodyhtert antibody
- TCS1 antibodyTelomerase associated protein 2 antibodyTelomerase Catalytic Subunit antibodyTelomerase Catalytic Subunit antibodyTelomerase reverse transcriptase antibodyTelomerase-associated protein 2 antibodyTelomere Reverse Transcriptase antibodyTelomere Reverse Transcriptase antibodyTERT antibodyTERT antibodyTERT_HUMAN antibodyTP2 antibodyTRT antibodyTRT antibody
Anti-Telomerase reverse transcriptase antibody [Y182] images
Anti-Telomerase reverse transcriptase antibody [Y182] (ab32020) at 1/1000 dilution + Hela cell lysate
Predicted band size : 127 kDa
Observed band size : 122 kDa (why is the actual band size different from the predicted?)
Ab32020, at a 1/50 dilution, staining Telomerase Reverse Transcriptase in HeLa cells by Immunofluorescence.
ab32020 staining Telomerase in human breast carcinoma cells by Immunocytochemistry/ Immunofluorescence. Cells were fixed with paraformaldehyde, permeabilized with 0.5% Triton x100 and blocking with 2% serum was performed for 30 minutes in 370C. Samples were incubated with primary antibody (1/100) in PBS for 1 hour 30 minutes at 37°C. An Alexa Fluor® 594-conjugated goat monoclonal to rabbit IgG was used at dilution at 1/75 as secondary antibody.
References for Anti-Telomerase reverse transcriptase antibody [Y182] (ab32020)
This product has been referenced in:
- Kar A et al. Metastases suppressor NME2 associates with telomere ends and telomerase and reduces telomerase activity within cells. Nucleic Acids Res 40:2554-65 (2012). WB, ICC/IF ; Human . Read more (PubMed: 22135295) »
- He Z et al. Revisited microanatomy of the corneal endothelial periphery: new evidence for continuous centripetal migration of endothelial cells in humans. Stem Cells 30:2523-34 (2012). IHC - Wholemount ; Human . Read more (PubMed: 22949402) »